Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Men's age, urinary symptoms, and heart health risks create different types of erectile dysfunction.

There is not enough evidence to support health claims about soy isoflavones.

Low-dose oral minoxidil can cause dizziness in women without lowering blood pressure, so careful monitoring is needed.

This study found that early-onset androgenetic alopecia is associated with higher prevalence of metabolic syndrome, atheroma plaques, and urinary symptoms related to prostate growth compared to controls.

This article reviews the updated ESHRE/ASRM criteria for diagnosing polycystic ovary syndrome, emphasizing the need for continued research and collaboration, but reports no new clinical results.

This review discusses the use of topical and oral minoxidil for pediatric hair disorders, pointing out the lack of guidelines and the potential risks associated with systemic absorption, but reports no clinical results.

This study found that low-dose oral minoxidil (≤5 mg/day) effectively increased hair number and diameter in men and women with androgenetic alopecia, and was generally well-tolerated with mostly mild adverse effects, although serious complications were rare and associated mainly with pre-existing heart conditions.

This review discusses the potential of low-dose oral minoxidil as a safe and effective treatment for certain hair disorders, including alopecia, but reports no new clinical results.

The document concludes that individualized treatment and lifestyle changes are important for managing menopause symptoms and health risks.

This scoping review aims to explore the impact of hormone therapy on the laboratory profiles of transgender people, identify evidence, and highlight literature gaps, particularly in developing countries.

This review discusses the genetics and variable phenotypic expression of nonclassic congenital adrenal hyperplasia, and reports no new clinical results; the authors call for further research on long-term health impacts and treatment strategies.

This review explores the potential impact of SARS-CoV-2 on benign prostatic hyperplasia and related lower urinary tract symptoms but reports no new clinical results, emphasizing the need for further studies to quantify these changes.

This abstract provides a narrative overview of polycystic ovary syndrome, discussing its symptoms and related health issues, and does not include new research findings.

This study found that one month after discharge, cardiovascular patients previously hospitalized for COVID-19 experienced reduced respiratory symptoms but increased reports of depression, hypercholesterolemia, fatigue, and sleep disorders.

This study found that one year after recovering from COVID-19, females without comorbidities reported long-COVID symptoms more frequently than males and experienced distinct cardiovascular differences, including lower arterial pressures and higher heart rates, despite fewer ECG abnormalities.

This study suggests that polycystic ovary syndrome symptoms are uncommon among women with metabolic syndrome, indicating it may represent only a specific subset within the broader context of metabolic syndrome.

The document concludes that managing PCOS involves treating symptoms and reducing long-term metabolic risks, with lifestyle changes being important.

This review examines the prevalence and symptoms of polycystic ovary syndrome (PCOS) across different ages, highlighting its varied dermatological and reproductive implications, but reports no new research findings.

This study found that patients with AA who have more severe symptoms may have a higher risk of metabolic syndrome and arterial stiffness, suggesting a need for cardiometabolic disease screening.

This review discusses Hutchinson-Gilford Progeria Syndrome, its symptomatology, and the progress in developing treatment strategies, emphasizing that while a cure remains elusive, advances in understanding the disease's molecular mechanisms show promise for future approaches.

This review discusses the various evidence-based and potential applications of metformin in treating and preventing symptoms and complications associated with polycystic ovary syndrome but reports no new clinical results.

This review covers cross-sex hormone therapy for gender dysphoria, noting improvements in psychological symptoms and quality of life but lacking definitive long-term safety data.

This paper reviews the complex pathophysiology of polycystic ovary syndrome, exploring how hormonal and metabolic disturbances contribute to its symptoms and related health risks, but it presents no new findings.

This study reports that obesity significantly influences cardiovascular and metabolic disturbances in women with PCOS, with overweight women experiencing more severe symptoms compared to their non-obese counterparts.

This study highlights the challenges faced by women with PCOS and emphasizes the importance of lifestyle changes, such as diet and weight loss, as the primary treatment strategy to manage symptoms and reduce associated health risks.

In this study, lifestyle changes, particularly weight loss, were reported to improve symptoms and prognosis of Polycystic Ovary Syndrome, especially in patients who are overweight or obese.

In this study, polycystic ovarian disease was identified as a prevalent chronic endocrinopathy among women of reproductive age, with common dermatological symptoms such as hirsutism, acne, and androgenic alopecia.

This update discusses guidelines for dermatology nurses and nurse practitioners on polycystic ovary syndrome but presents no new research findings; it emphasizes their role in early diagnosis through recognizing skin symptoms.

In this study, low-dose oral minoxidil for androgenetic alopecia was generally safe, showing small average changes in blood pressure and heart rate with infrequent cardiovascular issues, though monitoring is essential, especially in patients with conditions like hypertension or arrhythmias.

In this case report, a 23-year-old man experienced dizziness, blurred vision, malaise, and fatigue after excessive use of topical minoxidil for three days, with symptoms resolving once minoxidil was discontinued.